Proqr Therapeutics Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ProQR Therapeutics (NASDAQ:PRQR) Price Target Increased to $2 00 by Analysts at Citigroup

ProQR Therapeutics (NASDAQ:PRQR) Price Target Increased to $2 00 by Analysts at Citigroup
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sigma securitiesVirtu financialTower research capitalProqr therapeutics company profileBelvedere tradingFree reportModerate buyGet free reportResearch capitalFinancial markets

Citigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2 00

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) had its target price lifted by analysts at Citigroup from $1.80 to $2.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective suggests a potential upside of 2.56% from the company’s […]

Tower research capitalBelvedere tradingSigma securitiesProqr therapeutics company profileVirtu financialGet free reportResearch capitalFinancial markets

Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $3 80

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has been given a consensus rating of “Buy” by the four brokerages that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the […]

Blackrock incVirtu financialRenaissance technologiesJpmorgan chase coProqr therapeutics company profileTopco ltdGet free reportMarketbeat ratingsGet free

ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of Buy from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last […]

Jpmorgan chase coMarshall waceProqr therapeutics company profileRenaissance technologiesBlackrock incGet free reportTwo sigma investmentsSigma investmentsGet free

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of Buy by Analysts

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has earned a consensus rating of “Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in […]

Raymond jamesCapital partnersRenaissance technologiesProqr therapeutics company profileJpmorgan chase coGet free reportMarketbeat ratingsChardan capitalFinancial marketsAsset managementGet freeProqr therapeuticsNasdaq prqr